Efficacy of nitric oxide-liberating cream on pityriasis versicolor

Journal of Dermatological Treatment

Volumn 21, Issue 2, 2010, Pages 93-96

  Jowkar, Farideh ^a   Jamshidzadeh, Akram ^a   Pakniyat, Soroush ^a   Reza Namazi, Mohammad ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Efficacy; Nitric oxide; Pityriasis versicolor

Indexed keywords

CICLOPIROXOLAMINE; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NITRIC OXIDE; OXICONAZOLE; PLACEBO; POTASSIUM HYDROXIDE; SELENIUM SULFIDE; SULCONAZOLE; SULFACETAMIDE; OINTMENT;

ACNE; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; SKIN DISCOLORATION; SKIN IRRITATION; TINEA VERSICOLOR; TREATMENT DURATION; CHI SQUARE DISTRIBUTION; OINTMENT; SEVERITY OF ILLNESS INDEX; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NITRIC OXIDE; OINTMENTS; PLACEBOS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TINEA VERSICOLOR; TREATMENT OUTCOME;

EID: 76749146408     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630902887229     Document Type: Article

References (14)

1. Weller R, Ormerod AD, Hobson RP, Benjamin NJ. A randomized trial of acidifed nitrite cream in the treatment of tinea pedis. J Am Acad Dermatol. 1998;38:559-563.
2. Lowenstein CJ, Snyder SH. Nitric oxide, a novel biologic messenger. Cell. 1992;70:705-707.
3. Ormerod AD, White MI, Shah SA, Benjamin N. Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. Br J Dermatol. 1999;141:1051-1053.
4. Burkhart CG. Tinea versicolor. J Dermatol allergy. 1983;6:8-12.
5. Burkhart CG, Dvorak N, Stockard H. An unusual case of tinea versicolor in an immunosuppressed patient. Cutis. 1981;27:56-58.
6. Gaitanis G, Velegraki A, Alexopoulos EC, Chasapi V, Tsigonia A, Katsambas A. Distribution of Malassezia species in pityriasis versicolor and seborrhoeic dermatitis in Greece. typing of the major pityriasis versicolor isolate M. globosa. Br J Dermatol. 2006;154:854-859.
7. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, And pharmacology. Pharmacol rev. 1991;43:109-142.
8. Marletta MA. Nitric oxide: Biosynthesis and biological signifcance. Trends Biochem Sci. 1989;14:488-492.
9. Luscher TF. Endothelial control of vascular tone and growth. Clin Exp Hypertens (A). 1990;12:897-902.
10. Burns T, Breathnach S, Cox N, Griffiths C. Rook's textbook of dermatology.7th ed. Oxford: Blackwell; 2004;31.13
11. Fernandez-Nava HD, Laya-Cuadra B, Tianco EA. Comparison of single dose 400 mg versus 10-day 200 mg daily dose ketoconazole in the treatment of tinea versicolor. Int J Dermatol. 1997;36:64-66.
12. Faergemann J, Gupta AK, Al Mofadi A, Abanami A, Shareaah AA, Marynissen G. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol. 2002;138:69-73.
13. Karakas M, Durdu M, Memisoglu HR. Oral fluconazole in the treatment of tinea versicolor. J Dermatol. 2005;32:19-21.
14. Leeming JP, Sansom Je, Burton JL. Susceptibility of Malassezia furfur subgroups to terbinafne. Br J Dermatol. 1997;137:764-767.